Abstract
BackgroundRituximab is a a chimeric anti-CD20 monoclonal antibody approved to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in patients with inadequate response to first...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have